BioHarvest Sciences Inc. announces that it is now trading on the Frankfurt Stock Exchange.BioHarvest Sciences Inc. is now listed on the Frankfurt Stock Exchange under WKN: A2P3RM and the symbol 8MV. The company's shares continue to be listed on the Canadian Securities Exchange under the symbol C.BHSC. The Frankfurt listing will increase the visibility of the Company amongst European investors and will make it easier ...

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") announces that it is now trading on the Frankfurt Stock Exchange.

BioHarvest Sciences Inc. is now listed on the Frankfurt Stock Exchange (also known as the Deutsche Boerse AG) under WKN: A2P3RM and the symbol 8MV. The company's shares continue to be listed on the Canadian Securities Exchange under the symbol C.BHSC. The Frankfurt listing will increase the visibility of the Company amongst European investors and will make it easier for both institutional and retail investors across Europe to participate in the market for BioHarvest shares.

"We are very pleased to improve access to our shares for our growing followers across the European Union", stated Ilan Sobel, CEO of BioHarvest Sciences. "In the past 3 months, we have seen gains on both our trading volume and market cap as retail investors have discovered BioHarvest Sciences' unique value proposition and we will continue to support the growth of what is already a global community of BioHarvest shareholders. We are focused on bringing the power of our BioFarming technology to consumers across the globe and understand the importance of syncing our global operational footprint with providing easy access for shareholders across these geographies to be able to invest in our Company."

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company's technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to also become a leading supplier of cannabis for both medicinal and legal recreational purposes.

For more information visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes, might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/76717

News Provided by Newsfile via QuoteMedia

SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, CTXS, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-bmy-3/

Keep reading... Show less

Amgen To Present At The 2021 Evercore ISI Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the 2021 Evercore ISI Healthcare Conference at 5:10 p.m. ET on Tuesday Nov. 30, 2021. Rob Lenz M.D., Ph.D., senior vice president of Global Development at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

Keep reading... Show less

Amgen To Present At The 2021 Piper Sandler Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the 2021 Piper Sandler Healthcare Conference at 1:00 p.m. ET on Wednesday Dec. 1, 2021. Murdo Gordon executive vice president of Global Commercial Operations and Peter H. Griffith executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

Keep reading... Show less

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, HEPS, PTON and Z

The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://kclasslaw.com/cases/securities/nyse-bmy/

Keep reading... Show less

BMY, LSPD SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits

Bristol-Myers Squibb Company (NYSE:BMY)

Keep reading... Show less

Trodelvy® Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

-- Marketing Authorization Based on Phase 3 ASCENT Study Showing Trodelvy Significantly Improved Overall Survival vs. Physician's Choice of Chemotherapy in Metastatic Triple-Negative Breast Cancer --

-- Trodelvy Offers an Important New Treatment Option for People with this Aggressive Type of Metastatic Breast Cancer --

Keep reading... Show less

Top News

Related News